RecruitingNCT07482072

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

Imaging Biomarkers in Alzheimer's Disease - an Exploratory PET Study


Sponsor

Rigshospitalet, Denmark

Enrollment

60 participants

Start Date

Mar 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

Alzheimer's disease is the most common cause of dementia and affects a growing number of older adults. Although harmful proteins build up in the brain, we still do not fully understand why some brain regions are affected earlier or more severely than others. Many people with Alzheimer's disease also have problems with blood flow and sugar handling in the brain, and these changes may play an important role in disease development. People with type 2 diabetes are at especially high risk of developing Alzheimer's disease and often experience a more severe disease course. This pilot study aims to improve our understanding of how brain blood flow and sugar use are altered in Alzheimer's disease, and whether these changes differ in people with and without type 2 diabetes. We will study three groups: people with Alzheimer's disease without diabetes, people with Alzheimer's disease and type 2 diabetes, and healthy older individuals. By comparing these groups, we aim to identify early brain changes that may contribute to cognitive decline. Participants will undergo advanced brain imaging using positron emission tomography (PET) scans. One scan uses a radioactive sugar tracer to measure how the brain takes up and uses glucose. Importantly, a new non-invasive method will also allow us to estimate how efficiently glucose is transported from the blood into the brain. This is a key process that may be impaired in Alzheimer's disease, but has previously required invasive procedures. The new approach avoids arterial cannulation, making the study safer and more comfortable for participants. A second PET scan will assess brain blood flow and blood vessel function, including how well the vessels can respond to increased demand. Participants will also complete cognitive tests to assess memory and thinking abilities. Ultimately, this research may contribute to earlier diagnosis, better monitoring of disease progression, and development of new treatment strategies for Alzheimer's disease.


Eligibility

Min Age: 60 YearsMax Age: 90 Years

Inclusion Criteria3

  • suspected Alzheimer's disease
  • type 2 diabetes (group A)
  • able and willing to comply with study protocoil´´l

Exclusion Criteria7

  • type 2 diabetes (group B and C)
  • significant brain disease apart from dementia (group A and B)
  • significant vascular or neurological disease (group C)
  • active cancer treatment
  • history of alcohol or drug abuse
  • severe claustrophobia
  • pregnancy or breastfeeding

Interventions

DIAGNOSTIC_TEST[18F]FDG PET

Regional glucose metabolism as well as glucose transport will be assessed.

DIAGNOSTIC_TEST[11C]PIB

Early perfusion PET after acetazolamide infusion as well as late amyloid load will be assessed.


Locations(1)

Copenhagen University Hospital Herlev

Herlev, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07482072


Related Trials